Canada Life’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$86.1M Buy
192,144
+4,540
+2% +$2.12M 0.15% 121
2025
Q4
$85.1M Sell
187,604
-86,532
-32% -$37.3M 0.15% 122
2025
Q3
$108M Buy
274,136
+3,424
+1% +$1.43M 0.16% 119
2025
Q2
$121M Sell
270,712
-12
-0% -$5.53K 0.19% 104
2025
Q1
$131M Buy
270,724
+846
+0.3% +$394K 0.23% 84
2024
Q4
$109M Sell
269,878
-48,403
-15% -$22.4M 0.19% 97
2024
Q3
$148M Sell
318,281
-2,003
-0.6% -$962K 0.26% 73
2024
Q2
$150M Buy
320,284
+50,062
+19% +$21.7M 0.28% 62
2024
Q1
$113M Sell
270,222
-8,327
-3% -$3.52M 0.23% 87
2023
Q4
$113M Sell
278,549
-5,077
-2% -$1.88M 0.25% 79
2023
Q3
$98.6M Buy
283,626
+2,798
+1% +$979K 0.24% 84
2023
Q2
$99.3M Buy
280,828
+7,171
+3% +$2.42M 0.24% 84
2023
Q1
$86.3M Sell
273,657
-4,667
-2% -$1.4M 0.21% 93
2022
Q4
$80.7M Sell
278,324
-19,914
-7% -$6.07M 0.21% 101
2022
Q3
$86.2M Sell
298,238
-1,219
-0.4% -$351K 0.25% 81
2022
Q2
$84.5M Sell
299,457
-100,839
-25% -$27M 0.22% 92
2022
Q1
$110M Sell
400,296
-5,326
-1% -$1.26M 0.23% 82
2021
Q4
$88.8M Buy
405,622
+16,035
+4% +$3.12M 0.18% 107
2021
Q3
$71.1M Buy
389,587
+1,011
+0.3% +$197K 0.17% 119
2021
Q2
$78.3M Buy
388,576
+103,524
+36% +$21.7M 0.18% 117
2021
Q1
$60.9M Sell
285,052
-53,337
-16% -$11.7M 0.15% 155
2020
Q4
$79.8M Buy
338,389
+23,385
+7% +$5.37M 0.15% 150
2020
Q3
$85.7M Buy
315,004
+25,535
+9% +$7.04M 0.19% 124
2020
Q2
$83.7M Buy
289,469
+25,745
+10% +$6.98M 0.19% 121
2020
Q1
$63.1M Sell
263,724
-8,772
-3% -$2.01M 0.17% 134
2019
Q4
$59.2M Buy
272,496
+47,230
+21% +$9.56M 0.13% 175
2019
Q3
$38.2M Sell
225,266
-3,375
-1% -$597K 0.09% 239
2019
Q2
$41.9M Buy
228,641
+10,286
+5% +$1.8M 0.1% 228
2019
Q1
$40.1M Buy
218,355
+27,628
+14% +$5.1M 0.11% 205
2018
Q4
$30.4M Sell
190,727
-2,035
-1% -$353K 0.09% 230
2018
Q3
$37.2M Sell
192,762
-23,318
-11% -$4.15M 0.09% 229
2018
Q2
$36.8M Buy
216,080
+2,043
+1% +$317K 0.09% 239
2018
Q1
$34.9M Sell
214,037
-6,948
-3% -$1.13M 0.08% 243
2017
Q4
$33.1M Buy
220,985
+1,555
+0.7% +$230K 0.08% 258
2017
Q3
$32.9M Sell
219,430
-10,263
-4% -$1.54M 0.08% 251
2017
Q2
$29.6M Buy
229,693
+54,178
+31% +$6.52M 0.08% 264
2017
Q1
$19.2M Buy
175,515
+1,282
+0.7% +$113K 0.05% 346
2016
Q4
$12.9M Sell
174,233
-2,074
-1% -$169K 0.04% 422
2016
Q3
$15.4M Buy
176,307
+5,142
+3% +$486K 0.04% 375
2016
Q2
$14.7M Buy
171,165
+40,867
+31% +$3.53M 0.04% 379
2016
Q1
$10.3M Buy
130,298
+5,552
+4% +$502K 0.04% 397
2015
Q4
$15.7M Sell
124,746
-280
-0.2% -$33.8K 0.06% 302
2015
Q3
$13M Buy
125,026
+4,595
+4% +$590K 0.05% 328
2015
Q2
$14.8M Sell
120,431
-5,869
-5% -$740K 0.05% 345
2015
Q1
$14.9M Sell
126,300
-2,971
-2% -$356K 0.05% 354
2014
Q4
$15.3M Sell
129,271
-18,860
-13% -$2.12M 0.05% 351
2014
Q3
$16.7M Buy
148,131
+20,548
+16% +$1.96M 0.06% 334
2014
Q2
$12M Buy
127,583
+16,250
+15% +$1.14M 0.04% 387
2014
Q1
$7.83M Buy
111,333
+2,438
+2% +$193K 0.03% 470
2013
Q4
$8.13M Sell
108,895
-13,215
-11% -$920K 0.03% 462
2013
Q3
$9.24M Buy
122,110
+93,210
+323% +$7.42M 0.04% 413
2013
Q2
$2.31M Buy
+28,900
New +$2.13M 0.02% 389

Other funds holding VRTX

Canada Life's VRTX Position: Q1 2026 in Review

Canada Life increased its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, buying an estimated $2.12M and bringing the position to 192,144 shares worth $86.1M. The position accounts for 0.15% of the portfolio, ranked #121.

Canada Life first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $150M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Canada Life held 192,144 shares of Vertex Pharmaceuticals worth $86.1M as of Q1 2026.
  • Canada Life bought 4,540 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.12M.
  • Vertex Pharmaceuticals made up 0.15% of Canada Life's portfolio in Q1 2026, its #121 holding.
  • Canada Life first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Canada Life's Vertex Pharmaceuticals position peaked at $150M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.